Monoclonal antibodyPhase 3 trialInvestigational
Imfinzi
Generic name: durvalumab
How it works
Blocks PD-L1, a protein on cancer cells that can help them evade the immune system. By blocking PD-L1, the immune system is more likely to attack cancer cells.
Cancer types
Lung Cancer— All patients
Melanoma— All patients
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with median progression-free survival of approximately 5 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Radiotherapy and Immunotherapy for Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| New Cancer Treatment Combination Shows Promise in Lung and Head and Neck Cancers | Lung Cancer | phase-1 | Five (8.3%) patients had objective responses; 31 (51.7%) had stable disease. | Source → |
| Durvalumab as Consolidation for Limited Stage Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Combining two treatments for advanced prostate cancer | Prostate Cancer | phase-2 | Median radiographic progression-free survival was 5.0 months, and median overall survival was 19.1 months. | Source → |
| Durvalumab Study for Unresectable Lung Cancer in Russia | Lung Cancer | preclinical | — | Source → |
| Combining Chemotherapy and Immunotherapy for Lung Cancer | Lung Cancer | phase-2 | N2 nodal clearance was 73.3% (22/30) after treatment. | Source → |
| Timing of Durvalumab Treatment Affects Lung Cancer Survival | Lung Cancer | observational | When considering the timing of durvalumab, no significant survival difference was found when durvalumab was initiated on or before week 4: adjusted HR, 0.81 (95% CI, 0.62 to 1.05, = .07). | Source → |
| New Treatment Combination Shows Promise for Ovarian Cancer Patients | Ovarian Cancer | phase-2 | PFS36 rates are 47.4% (olaparib priming then olaparib-durvalumab), 48.7% (olaparib-cyclophosphamide then olaparib-durvalumab), and 35.1% (olaparib monotherapy). | Source → |
| Durvalumab and Radiation Therapy Improve Lung Cancer Outcomes | Lung Cancer | phase-3 | The 2- and 3-year local control rates in patients who received total radiation doses > 66 Gy were 80% and 75%, respectively. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.